Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: Have we chosen the best designs?

Edward V. Nunes, Samuel Ball, Robert Booth, Gregory Brigham, Donald A. Calsyn, Kathleen Carroll, Daniel J. Feaster, Denise Hien, Robert L. Hubbard, Walter Ling, Nancy M. Petry, John Rotrosen, Jeffrey Selzer, Maxine Stitzer, Susan Tross, Paul Wakim, Theresa Winhusen, George Woody

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Multisite effectiveness trials such as those carried out in the National Drug Abuse Treatment Clinical Trials Network (CTN) are a critical step in the development and dissemination of evidence-based treatments because they address how such treatments perform in real-world clinical settings. As Brigham et al. summarized in a recent article (G. S. Brigham, D. J. Feaster, P. G. Wakim, & C. L. Dempsey C. L., 2009), several possible experimental designs may be chosen for such effectiveness trials. These include (a) a new treatment intervention (Tx) is compared to an existing mode of community based treatment as usual (TAU): Tx versus TAU; (b) a new intervention is added to TAU and compared to TAU alone: Tx + TAU versus TAU; or (c) a new intervention is added to TAU and compared to a control condition added to TAU: Tx + TAU versus control + TAU. Each of these designs addresses a different question and has different potential strengths and weaknesses. As of December 2009, the primary outcome paper had been published for 16 of the multisite randomized clinical trials conducted in the CTN, testing various treatments for drug abuse, HIV risk behavior, or related problems. This paper systematically examines, for each of the completed trials, the experimental design type chosen and its original rationale, the main findings of the trial, and the strengths and weaknesses of the design in hindsight. Based on this review, recommendations are generated to inform the design of future effectiveness trials on treatments for substance abuse, HIV risk, and other behavioral health problems.

Original languageEnglish (US)
JournalJournal of Substance Abuse Treatment
Volume38
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 1 2010

Fingerprint

Substance-Related Disorders
Research Design
Clinical Trials
HIV
Risk-Taking
Randomized Controlled Trials
Health
Problem Behavior

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Clinical Psychology
  • Phychiatric Mental Health
  • Medicine (miscellaneous)

Keywords

  • Clinical trial
  • Design
  • Drug
  • Effectiveness
  • HIV

Cite this

Nunes, Edward V. ; Ball, Samuel ; Booth, Robert ; Brigham, Gregory ; Calsyn, Donald A. ; Carroll, Kathleen ; Feaster, Daniel J. ; Hien, Denise ; Hubbard, Robert L. ; Ling, Walter ; Petry, Nancy M. ; Rotrosen, John ; Selzer, Jeffrey ; Stitzer, Maxine ; Tross, Susan ; Wakim, Paul ; Winhusen, Theresa ; Woody, George. / Multisite effectiveness trials of treatments for substance abuse and co-occurring problems : Have we chosen the best designs?. In: Journal of Substance Abuse Treatment. 2010 ; Vol. 38, No. SUPPL. 1.
@article{d783b35001274ec9a6c949bc1d3e4403,
title = "Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: Have we chosen the best designs?",
abstract = "Multisite effectiveness trials such as those carried out in the National Drug Abuse Treatment Clinical Trials Network (CTN) are a critical step in the development and dissemination of evidence-based treatments because they address how such treatments perform in real-world clinical settings. As Brigham et al. summarized in a recent article (G. S. Brigham, D. J. Feaster, P. G. Wakim, & C. L. Dempsey C. L., 2009), several possible experimental designs may be chosen for such effectiveness trials. These include (a) a new treatment intervention (Tx) is compared to an existing mode of community based treatment as usual (TAU): Tx versus TAU; (b) a new intervention is added to TAU and compared to TAU alone: Tx + TAU versus TAU; or (c) a new intervention is added to TAU and compared to a control condition added to TAU: Tx + TAU versus control + TAU. Each of these designs addresses a different question and has different potential strengths and weaknesses. As of December 2009, the primary outcome paper had been published for 16 of the multisite randomized clinical trials conducted in the CTN, testing various treatments for drug abuse, HIV risk behavior, or related problems. This paper systematically examines, for each of the completed trials, the experimental design type chosen and its original rationale, the main findings of the trial, and the strengths and weaknesses of the design in hindsight. Based on this review, recommendations are generated to inform the design of future effectiveness trials on treatments for substance abuse, HIV risk, and other behavioral health problems.",
keywords = "Clinical trial, Design, Drug, Effectiveness, HIV",
author = "Nunes, {Edward V.} and Samuel Ball and Robert Booth and Gregory Brigham and Calsyn, {Donald A.} and Kathleen Carroll and Feaster, {Daniel J.} and Denise Hien and Hubbard, {Robert L.} and Walter Ling and Petry, {Nancy M.} and John Rotrosen and Jeffrey Selzer and Maxine Stitzer and Susan Tross and Paul Wakim and Theresa Winhusen and George Woody",
year = "2010",
month = "6",
day = "1",
doi = "https://doi.org/10.1016/j.jsat.2010.01.012",
language = "English (US)",
volume = "38",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "SUPPL. 1",

}

Nunes, EV, Ball, S, Booth, R, Brigham, G, Calsyn, DA, Carroll, K, Feaster, DJ, Hien, D, Hubbard, RL, Ling, W, Petry, NM, Rotrosen, J, Selzer, J, Stitzer, M, Tross, S, Wakim, P, Winhusen, T & Woody, G 2010, 'Multisite effectiveness trials of treatments for substance abuse and co-occurring problems: Have we chosen the best designs?', Journal of Substance Abuse Treatment, vol. 38, no. SUPPL. 1. https://doi.org/10.1016/j.jsat.2010.01.012

Multisite effectiveness trials of treatments for substance abuse and co-occurring problems : Have we chosen the best designs? / Nunes, Edward V.; Ball, Samuel; Booth, Robert; Brigham, Gregory; Calsyn, Donald A.; Carroll, Kathleen; Feaster, Daniel J.; Hien, Denise; Hubbard, Robert L.; Ling, Walter; Petry, Nancy M.; Rotrosen, John; Selzer, Jeffrey; Stitzer, Maxine; Tross, Susan; Wakim, Paul; Winhusen, Theresa; Woody, George.

In: Journal of Substance Abuse Treatment, Vol. 38, No. SUPPL. 1, 01.06.2010.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Multisite effectiveness trials of treatments for substance abuse and co-occurring problems

T2 - Have we chosen the best designs?

AU - Nunes, Edward V.

AU - Ball, Samuel

AU - Booth, Robert

AU - Brigham, Gregory

AU - Calsyn, Donald A.

AU - Carroll, Kathleen

AU - Feaster, Daniel J.

AU - Hien, Denise

AU - Hubbard, Robert L.

AU - Ling, Walter

AU - Petry, Nancy M.

AU - Rotrosen, John

AU - Selzer, Jeffrey

AU - Stitzer, Maxine

AU - Tross, Susan

AU - Wakim, Paul

AU - Winhusen, Theresa

AU - Woody, George

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Multisite effectiveness trials such as those carried out in the National Drug Abuse Treatment Clinical Trials Network (CTN) are a critical step in the development and dissemination of evidence-based treatments because they address how such treatments perform in real-world clinical settings. As Brigham et al. summarized in a recent article (G. S. Brigham, D. J. Feaster, P. G. Wakim, & C. L. Dempsey C. L., 2009), several possible experimental designs may be chosen for such effectiveness trials. These include (a) a new treatment intervention (Tx) is compared to an existing mode of community based treatment as usual (TAU): Tx versus TAU; (b) a new intervention is added to TAU and compared to TAU alone: Tx + TAU versus TAU; or (c) a new intervention is added to TAU and compared to a control condition added to TAU: Tx + TAU versus control + TAU. Each of these designs addresses a different question and has different potential strengths and weaknesses. As of December 2009, the primary outcome paper had been published for 16 of the multisite randomized clinical trials conducted in the CTN, testing various treatments for drug abuse, HIV risk behavior, or related problems. This paper systematically examines, for each of the completed trials, the experimental design type chosen and its original rationale, the main findings of the trial, and the strengths and weaknesses of the design in hindsight. Based on this review, recommendations are generated to inform the design of future effectiveness trials on treatments for substance abuse, HIV risk, and other behavioral health problems.

AB - Multisite effectiveness trials such as those carried out in the National Drug Abuse Treatment Clinical Trials Network (CTN) are a critical step in the development and dissemination of evidence-based treatments because they address how such treatments perform in real-world clinical settings. As Brigham et al. summarized in a recent article (G. S. Brigham, D. J. Feaster, P. G. Wakim, & C. L. Dempsey C. L., 2009), several possible experimental designs may be chosen for such effectiveness trials. These include (a) a new treatment intervention (Tx) is compared to an existing mode of community based treatment as usual (TAU): Tx versus TAU; (b) a new intervention is added to TAU and compared to TAU alone: Tx + TAU versus TAU; or (c) a new intervention is added to TAU and compared to a control condition added to TAU: Tx + TAU versus control + TAU. Each of these designs addresses a different question and has different potential strengths and weaknesses. As of December 2009, the primary outcome paper had been published for 16 of the multisite randomized clinical trials conducted in the CTN, testing various treatments for drug abuse, HIV risk behavior, or related problems. This paper systematically examines, for each of the completed trials, the experimental design type chosen and its original rationale, the main findings of the trial, and the strengths and weaknesses of the design in hindsight. Based on this review, recommendations are generated to inform the design of future effectiveness trials on treatments for substance abuse, HIV risk, and other behavioral health problems.

KW - Clinical trial

KW - Design

KW - Drug

KW - Effectiveness

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=77950227170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950227170&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.jsat.2010.01.012

DO - https://doi.org/10.1016/j.jsat.2010.01.012

M3 - Article

C2 - 20307801

VL - 38

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - SUPPL. 1

ER -